1. Home
  2. BBW vs OMER Comparison

BBW vs OMER Comparison

Compare BBW & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBW
  • OMER
  • Stock Information
  • Founded
  • BBW 1997
  • OMER 1994
  • Country
  • BBW United States
  • OMER United States
  • Employees
  • BBW N/A
  • OMER N/A
  • Industry
  • BBW Recreational Games/Products/Toys
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBW Consumer Discretionary
  • OMER Health Care
  • Exchange
  • BBW Nasdaq
  • OMER Nasdaq
  • Market Cap
  • BBW 527.5M
  • OMER 579.5M
  • IPO Year
  • BBW 2004
  • OMER 2009
  • Fundamental
  • Price
  • BBW $39.09
  • OMER $9.33
  • Analyst Decision
  • BBW Strong Buy
  • OMER Buy
  • Analyst Count
  • BBW 3
  • OMER 4
  • Target Price
  • BBW $54.33
  • OMER $22.50
  • AVG Volume (30 Days)
  • BBW 328.8K
  • OMER 1.1M
  • Earning Date
  • BBW 03-13-2025
  • OMER 11-13-2024
  • Dividend Yield
  • BBW 2.05%
  • OMER N/A
  • EPS Growth
  • BBW 8.16
  • OMER N/A
  • EPS
  • BBW 3.79
  • OMER N/A
  • Revenue
  • BBW $495,235,000.00
  • OMER N/A
  • Revenue This Year
  • BBW $2.53
  • OMER N/A
  • Revenue Next Year
  • BBW $2.59
  • OMER N/A
  • P/E Ratio
  • BBW $10.32
  • OMER N/A
  • Revenue Growth
  • BBW 2.76
  • OMER N/A
  • 52 Week Low
  • BBW $21.42
  • OMER $2.61
  • 52 Week High
  • BBW $48.23
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • BBW 39.91
  • OMER 49.55
  • Support Level
  • BBW $38.76
  • OMER $8.21
  • Resistance Level
  • BBW $42.12
  • OMER $11.26
  • Average True Range (ATR)
  • BBW 1.81
  • OMER 0.93
  • MACD
  • BBW -1.00
  • OMER -0.20
  • Stochastic Oscillator
  • BBW 8.56
  • OMER 31.37

About BBW Build-A-Bear Workshop Inc.

Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: